JP2024501771A - 抗pd-l1抗体及びその融合タンパク質 - Google Patents

抗pd-l1抗体及びその融合タンパク質 Download PDF

Info

Publication number
JP2024501771A
JP2024501771A JP2023540927A JP2023540927A JP2024501771A JP 2024501771 A JP2024501771 A JP 2024501771A JP 2023540927 A JP2023540927 A JP 2023540927A JP 2023540927 A JP2023540927 A JP 2023540927A JP 2024501771 A JP2024501771 A JP 2024501771A
Authority
JP
Japan
Prior art keywords
seq
substitution
amino acid
acid sequence
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023540927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501771A5 (cg-RX-API-DMAC7.html
Inventor
パン,リー
チェー,ジェニー
シュー,リーフイ
Original Assignee
パレオン ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パレオン ファーマシューティカルズ インコーポレイテッド filed Critical パレオン ファーマシューティカルズ インコーポレイテッド
Publication of JP2024501771A publication Critical patent/JP2024501771A/ja
Publication of JP2024501771A5 publication Critical patent/JP2024501771A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023540927A 2021-01-06 2022-01-06 抗pd-l1抗体及びその融合タンパク質 Pending JP2024501771A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163134412P 2021-01-06 2021-01-06
US63/134,412 2021-01-06
PCT/US2022/011504 WO2022150521A1 (en) 2021-01-06 2022-01-06 Anti-pd-l1 antibodies and fusion proteins thereof

Publications (2)

Publication Number Publication Date
JP2024501771A true JP2024501771A (ja) 2024-01-15
JP2024501771A5 JP2024501771A5 (cg-RX-API-DMAC7.html) 2025-01-09

Family

ID=82357548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023540927A Pending JP2024501771A (ja) 2021-01-06 2022-01-06 抗pd-l1抗体及びその融合タンパク質

Country Status (10)

Country Link
US (1) US20240067729A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274614A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024501771A (cg-RX-API-DMAC7.html)
KR (1) KR20230131236A (cg-RX-API-DMAC7.html)
CN (1) CN116829188A (cg-RX-API-DMAC7.html)
AU (1) AU2022206264A1 (cg-RX-API-DMAC7.html)
CA (1) CA3173557A1 (cg-RX-API-DMAC7.html)
IL (1) IL304190A (cg-RX-API-DMAC7.html)
MX (1) MX2023008028A (cg-RX-API-DMAC7.html)
WO (1) WO2022150521A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7462560B2 (ja) 2018-01-03 2024-04-05 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
JP2023532021A (ja) * 2020-07-03 2023-07-26 パレオン ファーマシューティカルズ インコーポレイテッド プロテアーゼ感受性が低減された組換えシアリダーゼ、シアリダーゼ融合タンパク質、及びその使用方法
KR20230138473A (ko) * 2021-01-06 2023-10-05 팔레온 파마슈티칼스 인크. 시알리다제-her2-항체 융합 단백질들 및 이의 사용방법
CN120779021A (zh) * 2024-04-08 2025-10-14 菲鹏生物股份有限公司 抗体缀合物及其用途
EP4744681A1 (en) 2024-08-16 2026-05-20 Shanghai Bao Pharmaceuticals Co., Ltd. COMPLEX TARGETING TARGET CELLS AND ITS USE

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504336A (ja) * 2012-12-21 2016-02-12 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. ヒトプログラム死リガンド1(pd−l1)に結合する抗体
WO2018231661A1 (en) * 2017-06-12 2018-12-20 Tianxin Wang Methods and reagents to treat tumor and cancer
US20200332009A1 (en) * 2017-12-27 2020-10-22 Innovent Biologics (Suzhou) Co., Ltd. Anti-pd-l1 antibody and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG170091A1 (en) * 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof
KR20150131208A (ko) * 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd8에의 항원 결합 구조체들
MA42971A (fr) * 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
EP3277320A4 (en) * 2015-03-30 2018-08-01 Stcube, Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
JP7462560B2 (ja) * 2018-01-03 2024-04-05 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
EP3569618A1 (en) * 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
CN111606995B (zh) * 2019-06-04 2021-02-12 优睿赛思(武汉)生物科技有限公司 抗人pd-l1单克隆抗体及其应用
CN111763259B (zh) * 2020-09-03 2020-12-15 北京百奥赛图基因生物技术有限公司 抗cd40抗体及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504336A (ja) * 2012-12-21 2016-02-12 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. ヒトプログラム死リガンド1(pd−l1)に結合する抗体
WO2018231661A1 (en) * 2017-06-12 2018-12-20 Tianxin Wang Methods and reagents to treat tumor and cancer
US20200332009A1 (en) * 2017-12-27 2020-10-22 Innovent Biologics (Suzhou) Co., Ltd. Anti-pd-l1 antibody and uses thereof

Also Published As

Publication number Publication date
IL304190A (en) 2023-09-01
AU2022206264A1 (en) 2023-07-20
EP4274614A4 (en) 2025-06-18
EP4274614A1 (en) 2023-11-15
CA3173557A1 (en) 2022-07-14
US20240067729A1 (en) 2024-02-29
CN116829188A (zh) 2023-09-29
MX2023008028A (es) 2023-08-14
WO2022150521A1 (en) 2022-07-14
KR20230131236A (ko) 2023-09-12

Similar Documents

Publication Publication Date Title
JP7462560B2 (ja) 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
US20240067729A1 (en) Anti-pd-l1 antibodies and fusion proteins thereof
JP7777988B2 (ja) 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法
JP2023532021A (ja) プロテアーゼ感受性が低減された組換えシアリダーゼ、シアリダーゼ融合タンパク質、及びその使用方法
US20240059792A1 (en) Sialidase-her2-antibody fusion proteins and methods of use thereof
US20220372458A1 (en) Sialidase-pd-l1-antibody fusion proteins and methods of use thereof
US20260078159A1 (en) NOVEL PD1-TARGETED IL-15 IMMUNOCYTOKINE and VITOKINE FUSIONS
US20220387616A1 (en) Sialidase-her2-antibody fusion proteins and methods of use thereof
JP2024501770A (ja) シアリダーゼ-pd-1-抗体融合タンパク質及びその使用方法
US20220380742A1 (en) Sialidase-cd20-antibody fusion proteins and methods of use thereof
WO2025217138A1 (en) Recombinant human sialidases, sialidase fusion proteins, and methods of using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260414